Dr. Eric Whitman, MD

Medicare patients and services

Medicare patients, 2024

303

Services billed

902

Patients’ average age

77

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 15 companies reported 88 payments worth $72,165 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New Jersey →

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $291,407 in research payments for these studies, mostly to the institutions running them.

• A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Sta…
  Merck Sharp & Dohme LLC
• NCT02360579
  Iovance Biotherapeutics, Inc.
• Study name not reported
  Iovance Biotherapeutics, Inc.
• A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
  Ascendis Pharma Endocrinology Inc · Active, not recruiting · NCT05081609
• A Phase 3, Randomized, Double-blinded, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Radioiodine Refractory Defferentiated Thyroid Cancer who have Progressed after Prior VEGFR Targeted Therapy
  Exelixis Inc.
• Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors
  Boehringer Ingelheim Pharmaceuticals, Inc.
• BNT111-01
  BioNTech SE
• BNT111
  BioNTech SE
• Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05352672

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other General Surgery clinicians in Morristown

• Kai A. Bickenbach, MD
• Mark A. Bishara, M.D.
• Samuel D. Echeverri, MD
• Igor G. Elyash, D.O.
• Marcella Fornari, DO
• Leah S. Gendler, M.D.
• Kory Heiken, MD
• Roy A. Henseler, MD